+420.1%
HUT vs GSK
+94.9%
+325.2%
-95.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.2% | -1.9% | +8.1% | +6.6% |
| 7D | +17.8% | -1.8% | +19.6% | +18.3% |
| 30D | +0.8% | -2.2% | +3.0% | +1.1% |
| 3M | -26.8% | -1.8% | -25.0% | -27.1% |
| 6M | +72.6% | -10.6% | +83.2% | +76.6% |
| YTD | +103.6% | +4.4% | +99.2% | +98.5% |
| 1Y | +265.3% | +30.4% | +234.9% | +228.8% |
| 3Y | +689.4% | +60.1% | +629.3% | +504.9% |
| 5Y | +75.3% | +46.8% | +28.6% | +40.0% |
| All | +420.1% | +94.9% | +325.2% | +254.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling